Skynner Michael sold $10K of BCYC
Skynner Michael (CHIEF SCIENTIFIC OFFICER) sold 2,391 shares of BICYCLE THERAPEUTICS PLC (BCYC) at an average of $4.28 ($4.27–$4.31) across 2 trades over 2026-07-02 to 2026-07-06.
How this was made
The 30-second read
Why it matters
The newest fact is the specific open-market sale by the Chief Scientific Officer (2,391 shares; ~$4.2789 weighted avg).
Market read
Traders may note the insider sale for sentiment/positioning, but it does not introduce new fundamentals or guidance.
What to watch
Insider sales can be driven by diversification/tax needs; without additional filings (e.g., grants, option exercises, or larger subsequent trades), the signal is likely limited.
Background
This is an SEC Form 4 insider transaction disclosure for Bicycle Therapeutics PLC (BCYC).
Ticker impact
Skynner Michael, BCYC’s Chief Scientific Officer, sold 2,391 shares in open-market trades at ~$4.27–$4.31 (Form 4 filed July 7).
Low likelihood of a sustained price move solely from this sale; any impact would be short-lived unless paired with other catalysts.
The filing is an open-market sale with modest dollar value (~$10.2k) and no 10b5-1 plan stated; insider sales are typically not directional without additional context.
Market effects
No clear sector read-through; this is a single-company insider transaction without new clinical/regulatory/product information.
None indicated.
None indicated.
Counterpoint
The absence of a stated 10b5-1 plan could prompt traders to scrutinize timing, but the transaction size is still small versus typical market-moving thresholds.
Key entities
- issuerBicycle Therapeutics PLC
Subject of the Form 4 insider transaction disclosure.
- insiderSkynner Michael
Chief Scientific Officer who sold shares in open-market trades.